Lv519
1130 积分 2024-12-05 加入
Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
1天前
已完结
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
6天前
已完结
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
20天前
已完结
Design and validation of an LC-MS/MS method for simultaneous quantification of asymmetric dimethylguanidino valeric acid, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma
23天前
已完结
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion
29天前
已完结
TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of peripheral MTAP-deleted solid tumors
29天前
已完结
Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR Mutant Non-Small Cell Lung Cancer
1个月前
已完结
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
1个月前
已完结
Discovery and development of Krazati (adagrasib/MRTX849), a potent, selective, orally bioavailable, covalent KRASG12C(OFF) inhibitor
1个月前
已完结
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
1个月前
已完结
皖公网安备34019202002308
